PATHOGENETIC ASPECTS OF THE WOUND CARE IN DIABETIC PATIENTS. A NEW SILVER ALGINATE DRESSING FIBROCLEAN AG: WHAT ARE BENEFITS?

It is well-known that multidisciplinary approaches allow to heal foot ulcers in 70–95 % of diabetic patients. In order to make an effective, local treatment, it is important to consider all pathogenic components of the wound healing process. Foot ulcers in diabetic patients tend to be chronic. The main objective of the local treatment is to create an optimal environment for tissue regeneration. The management of exudating, infected wounds usually represents the biggest difficulties in terms of selecting an optimal dressing. An overview of the results of the research shows that a new silver alginate dressing Fibroclean Ag has high strength and absorbency, which allows changing the bandage less and by this reducing the risk of spontaneous trauma. An additional atraumatic quality of the dressing is specified by the presence of the hyaluronic acid in the structure. The results of the research show that the antibacterial activity Fibroclean Ag corresponds to the spectrum of microorganisms most frequently encountered in diabetic foot ulcers. At the same time the bandage is effective against strains in the form of a biofilm, and outside of it. The important quality of this dressing is a reasonable cost. Thus, we can talk about a feasibility of using Fibroclean Ag in the local treatment of heavily exudating diabetic foot ulcers. At the same time, it should be remembered that the local treatment of wounds can be just as effective as part of a comprehensive treatment. For the detailed study of the properties of the dressing, it is necessary to conduct an additional research about the effectiveness of its usage in different groups of patients with diabetic foot ulcers.

1. Международное соглашение по диабетической стопе. Составлено Международной рабочей группой по диабетической стопе. М.: Берег, 2000. 96 с. [International treaty for the diabetic foot. Made up by the International Task Force for the diabetic foot. Moscow: Bereg, 2000. 96 p. (In Russ.)].

2. International Consensus on the Diabetic Foot, 2011.

3. International Diabetes Federation. Diabetes Atlas. 6th еd., 2014.

4. American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care: 7–8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care 1999;22(8): 1354–60.

5. Удовиченко О. В., Галстян Г. Р. Алгоритмы выбора перевязочного материала для лечения синдрома диабетической стопы (на при мере повязок фирмы Paul Hartmann). Сахарный диабет 2006;(1):46–

6. [Udovichenko O. V., Galstyan G. R. Algorithms of selection of dressing materials for treatment of the diabetic foot syndrome

7. (by the examples of Paul Hartmann dressings). Sakharnyi Diabet = Diabetes Mellitus 2006;(1):46–52. (In Russ.)].

8. Токмакова А. Ю., Страхова Г. Ю., Галстян Г. Р. Современная концепция ведения больных с хроническими ранами и сахарным диабетом. Сахарный диабет 2005;(1):42–8. [Tokmakova A. Yu., Strakhova G. Yu., Galstyan G. R. Modern concept of management of patients with chronic wounds and diabetes. Sakharnyi Diabet = Diabetes Mellitus 2005;(1):42–8. (In Russ.)].

9. Percival S. L., Thomas J. G., Williams D. W. Biofilms and bacterial imbalances in chronic wounds: anti-Koch. Int Wound J 2010;7(3):169–75.

10. Percival S. L., Slon W., Linton S. et al. The antimicrobial efficacy of a silver alginate dressing against a broad spectrum of clinically relevant wound isolates. Int Wound J 2011;8(3):237–43.

11. Lipsky B. A., Berendt A. R., Deery H. G. et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39(7):885–910.

12. Cavanagh P., Lipsky B. A., Bradbury A. W., Botek G. Treatment for diabetic foot ulcers. Lancet 2005;366(9498):1725–35.

13. Lipsky B. A., Itani K., Norden C.; Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate. Clin Infect Dis 2004;38(1):17–24.

14. Toy L. W., Macera L. Evidence-based review of silver dressing use on chronic wounds. J Am Acad Nurse Pract 2011;23(4):183–92.

15. Gove J., Hampton S., Smith G. еt al. Using the exudate decision algorithm to evaluate wound dressings. Br J Nurs 2014;23(6):S24, S26–9.

16. Ozaki C. K., Hamdan A. D., Barshes N. R. et al. Prospective, randomized, multi-institutional clinical trial of a silver alginate dressing to reduce lower extremity vascular surgery wound complications. J Vasc Surg 2015;61(2):419–27. e1.

17. Dumville J. C., O,Meara S., Deshpande S., Speak K. Alginate dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2013;6:CD009110.

18. Hooper S. J., Percival S. L., Hill K. E. et al. The visualisation and speed of kill of wound isolates on a silver alginate dressing. Int Wound J 2012;9(6):633–42.

19. Percival S. L., Cochrane C. A. MMPs and bacterial enzymes. In: S. L. Percival, K. Cutting (eds.). Microbiology of Wounds. New York: CRC Press, 2010.

20. Gethin G. Understanding the significance of surface pH in chronic wounds. Wounds UK 2007;3(3):52–6.

21. Percival S. L., Thomas J., Linton S. et аl. The antimicrobial efficacy of silver on anti bioticresistant bacteria isolated from burn wounds. Int Wound J 2011;8(3):237–43.